Stop TB Partnership

Last updated
StopTBLogo RGB.svg

The Stop TB Partnership was established in 2001 to eliminate tuberculosis as a public health problem. Its 2000 partner organizations include international, nongovernmental and governmental organizations and patient groups. The secretariat is based in Geneva, Switzerland, and, since 2015, has been administered by UNOPS. Previously it was 12 hosted by the World Health Organization. [1]

Contents

It is governed by a Board, [2] supported by two standing board committees, the Executive Committee, and the Finance Committee. The current Executive Director of the Stop TB Partnership is Dr. Lucica Ditiu. [3] The STBP Board provides leadership and direction, ensures coordination within the Stop TB Partnership, and monitors the implementation of agreed policies, plans, and activities of the Secretariat.

History

The Stop TB Initiative was established following the meeting of the First Session of the Ad Hoc Committee on the Tuberculosis Epidemic held in London in March 1998. [4] In March 2000 the Stop TB Partnership produced the Amsterdam Declaration to Stop TB, which called for action from ministerial delegations of 20 countries with the highest burden of TB. That same year the World Health Assembly endorsed the establishment of a Global Partnership to Stop TB. [5]

Global Plan to End Tuberculosis

The Global Plan to End TB, 2023-2030 [6] is a plan for ending TB as a public health challenge by 2030. It is produced by the Stop TB partnership and provides a blueprint of priority actions required and a detailed estimate of financial resources needed to end TB. This Global Plan builds on the previous edition, which laid out priority actions for 2018-2022, informed by global commitments member states endorsed at the 2018 United Nations High-Level Meeting (UNHLM) on TB. The resource needs estimates from this Global Plan include resources needed for implementing TB care and prevention and R&D into new tools. This Global Plan has already informed the Global Fund Investment Case and the 2022 G20 deliberations on TB. It calls on funders to contribute $5 billion annually for TB R&D. In 2021, only $1 billion was raised. [7]

Prior to this, five other plans were produced:

The first Global Plan to Stop TB 2001-2005 provided a coherent agenda to rally key new partners, push forward research and development, and have a rapid impact on TB in the areas suffering most from the epidemic It focused on the emerging challenge of rising drug resistance in TB and HIV infection.

The second Global Plan to Stop TB 2006-2015 was launched in Davos, Switzerland at the World Economic Forum. The total cost of the Plan - US$56 billion - represented a threefold increase in annual investment in TB control compared with the first Global Plan. The Plan set out to reduce TB incidence and reach the Partnership’s targets for 2015 of halving TB prevalence and deaths compared with 1990 levels.

The third Global Plan to Stop TB 2011-2015 focused on scaling up existing interventions for the diagnosis and treatment of TB and introducing new technologies and notably new diagnostic tests.

The fourth Global Plan to End TB 2016–2020 took the End TB Strategy as its foundation and provides countries and policymakers with a path towards achieving the Strategy’s milestones.

The fifth Global Plan to End TB 2018-2022 aligned with the Political Declaration of the UN High-Level Meeting (UNHLM) on the Fight Against TB. It provided an estimate of the resources needed to achieve the targets and commitments set at the UNHLM on TB in September 2018 by the deadline of December 2022.

Main activities

The Partnership's activities focus chiefly on raising awareness about TB and advocating for greater commitment to and funding for TB prevention, treatment and research. [8]

Global Drug Facility

GDF Drugs distributed by doctors Stop TB Partnership GDF programme in action.png
GDF Drugs distributed by doctors

The Stop TB Partnership’s Global Drug Facility (GDF) [9] has changed the landscape of TB care by working closely with countries, suppliers, donors, and other stakeholders to vastly increase global access to the latest quality-assured, affordable TB treatments and diagnostics for people affected by TB, whoever and wherever they are [10] . GDF delivers a market solution to a market failure by offering affordable, life-saving TB medicines and diagnostic tools [11] for countries that otherwise would not be able to access them and offering a financial return for drug and device developers that keeps them on the hunt for innovations.  

TB REACH  

The Stop TB Partnership TB Reach initiative is a multilateral funding mechanism that provides funding to partners to test innovative approaches and technologies to find and treat people with TB in the world’s most impoverished communities [12] . TB REACH shows the importance of reaching people, whether with drones, donkeys, or young people on motorbikes, and whether using molecular tests, new drugs, or 125-year-old microscopy.  

Challenge Facility for Civil Society

Reaching out to communities TB REACH in action.png
Reaching out to communities

The Stop TB Partnership Challenge Facility for Civil Society (CFCS), a grant mechanism supported by USAID, L'Initiative by Expertise France, and the Global Fund Strategic Initiative, empowers grassroots organizations and TB-affected communities often overlooked in the fight against tuberculosis [13] . By funding innovative and technically sound interventions, the CFCS aims to elevate these vital groups to recognized partners in both national and global TB responses [14] . This support enables community and civil society actors to engage in impactful advocacy, access essential services, and ensure governments uphold their commitments to the United Nations Political Declaration on TB [15] . The ultimate goal is to foster robust networks within civil society and TB-affected communities that are accountable, supportive, and actively involved in shaping and enhancing TB eradication efforts, promoting human rights and gender equity along the way.

Reviews

GiveWell review

Charity evaluator GiveWell first reviewed the Stop TB Partnership in July 2009. [16] At the time, the Stop TB Partnership was given a 3 star rating, the highest possible. Until November 2011, the Stop TB Partnership was among GiveWell's top-rated charities, second only to VillageReach.[ citation needed ]

In November 2011, GiveWell published an updated review of Stop TB [17] and concluded that "The Stop TB Partnership does not currently qualify for our highest ratings." They elaborated by saying that: "As of November 2011, we do not have a clear understanding of Stop TB's room for more funding. We have discussed this question with Stop TB and hope to improve our understanding of this in the future."

Employee treatment

On September 12, 2020, The New York Times published an article on the Stop TB Partnership titled "A Global Health Star Under Fire". [18] The article states that "the leader of a global campaign to prevent tuberculosis has been accused of bullying and harassing employees, and creating a poisonous work environment especially for people of color, according to interviews with current and former staff members and internal documents obtained by The New York Times." [19]

The Treatment Action Group released a statement condemning the reported bullying, harassment, and racism at the Stop TB Partnership and called on the Stop TB Partnership Board to commission an independent review into the allegations. [20]

Related Research Articles

<span class="mw-page-title-main">Tuberculosis</span> Infectious disease

Tuberculosis (TB), also known colloquially as the "white death", or historically as consumption, is an infectious disease usually caused by Mycobacterium tuberculosis (MTB) bacteria. Tuberculosis generally affects the lungs, but it can also affect other parts of the body. Most infections show no symptoms, in which case it is known as latent tuberculosis. Around 10% of latent infections progress to active disease which, if left untreated, kill about half of those affected. Typical symptoms of active TB are chronic cough with blood-containing mucus, fever, night sweats, and weight loss. Infection of other organs can cause a wide range of symptoms.

<i>Mycobacterium bovis</i> Species of bacterium

Mycobacterium bovis is a slow-growing aerobic bacterium and the causative agent of tuberculosis in cattle. It is related to Mycobacterium tuberculosis, the bacterium which causes tuberculosis in humans. M. bovis can jump the species barrier and cause tuberculosis-like infection in humans and other mammals.

<span class="mw-page-title-main">World Tuberculosis Day</span> Global public health campaign

World Tuberculosis Day, observed on 24 March each year, is designed to build public awareness about the global epidemic of tuberculosis (TB) and efforts to eliminate the disease. In 2018, 10 million people fell ill with TB, and 1.5 million died from the disease, mostly in low and middle-income countries. This also makes it the leading cause of death from an infectious disease.

<span class="mw-page-title-main">The Global Fund to Fight AIDS, Tuberculosis and Malaria</span> International organization

The Global Fund to Fight AIDS, Tuberculosis and Malaria is an international financing and partnership organization that aims to "attract, leverage and invest additional resources to end the epidemics of HIV/AIDS, tuberculosis and malaria to support attainment of the Sustainable Development Goals established by the United Nations". This multistakeholder international organization maintains its secretariat in Geneva, Switzerland. The organization began operations in January 2002. Microsoft founder Bill Gates was one of the first donors to provide seed money for the partnership. From January 2006 it has benefited from certain US Privileges, Exemptions, and Immunities under executive order 13395, which conferred International Organizations Immunities Act status on it.

TB Alliance is a not-for-profit product development partnership (PDP) dedicated to the discovery and development of new, faster-acting and affordable tuberculosis (TB) medicines. Since its inception in 2000, TB Alliance has worked to grow the field of available treatments for TB and now manages the largest pipeline of new TB drugs in history. It was founded in Cape Town, South Africa, and has since expanded. It is headquartered in New York City and has a regional office in Pretoria.

<span class="mw-page-title-main">Drugs for Neglected Diseases Initiative</span> Non-profit organization

The Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients' needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected diseases, notably leishmaniasis, sleeping sickness, Chagas disease, malaria, filarial diseases, mycetoma, paediatric HIV, cryptococcal meningitis, hepatitis C, and dengue. DNDi's malaria activities were transferred to Medicines for Malaria Venture (MMV) in 2015.

<span class="mw-page-title-main">Unitaid</span> Global health initiative

Unitaid is a global health initiative that works with partners to bring about innovations to prevent, diagnose and treat major diseases in low- and middle-income countries, with an emphasis on tuberculosis, malaria, and HIV/AIDS and its deadly co-infections. Founded in 2006, the organization funds the final stages of research and development of new drugs, diagnostics and disease-prevention tools, helps produce data supporting guidelines for their use, and works to allow more affordable generic medicines to enter the marketplace in low- and middle-income countries. Hosted by the World Health Organization (WHO) in Geneva, Unitaid was established by the governments of Brazil, Chile, France, Norway and the United Kingdom.

<span class="mw-page-title-main">Extensively drug-resistant tuberculosis</span> Tuberculosis that is resistant to the most effective drugs

Extensively drug-resistant tuberculosis (XDR-TB) is a form of tuberculosis caused by bacteria that are resistant to some of the most effective anti-TB drugs. XDR-TB strains have arisen after the mismanagement of individuals with multidrug-resistant TB (MDR-TB).

<span class="mw-page-title-main">Multidrug-resistant tuberculosis</span> Medical condition

Multidrug-resistant tuberculosis (MDR-TB) is a form of tuberculosis (TB) infection caused by bacteria that are resistant to treatment with at least two of the most powerful first-line anti-TB medications (drugs): isoniazid and rifampin. Some forms of TB are also resistant to second-line medications, and are called extensively drug-resistant TB (XDR-TB).

The National Tuberculosis Elimination Programme (NTEP), earlier known as the Revised National Tuberculosis Control Programme (RNTCP), is the Public Health initiative of the Government of India that organizes its anti-Tuberculosis efforts. It functions as a flagship component of the National Health Mission (NHM) and provides technical and managerial leadership to anti-tuberculosis activities in the country. As per the National Strategic Plan 2017–25, the program has a vision of achieving a "TB free India",with a strategies under the broad themes of "Prevent, Detect,Treat and Build pillars for universal coverage and social protection". The program provides, various free of cost, quality tuberculosis diagnosis and treatment services across the country through the government health system.

<span class="mw-page-title-main">Bedaquiline</span> Medication used to treat tuberculosis

Bedaquiline, sold under the brand name Sirturo, is a medication used to treat active tuberculosis. Specifically, it is used to treat multi-drug-resistant tuberculosis (MDR-TB) along with other medications for tuberculosis. It is used by mouth.

<span class="mw-page-title-main">Tuberculosis in China</span>

Tuberculosis is a serious public health problem in China. China has the world's third largest cases of tuberculosis, but progress in tuberculosis control was slow during the 1990s. Detection of tuberculosis had stagnated at around 30% of the estimated total of new cases, and multidrug-resistant tuberculosis was a major problem. These signs of inadequate tuberculosis control can be linked to a malfunctioning health system. The spread of severe acute respiratory syndrome (SARS) in 2003, brought to light substantial weaknesses in the country's public health system. After the government realized the impact that the SARS outbreak had on the country, they increased leadership in their health department. After the SARS epidemic was brought under control, the government increased its commitment and leadership to tackle public health problems and, among other efforts, increased public health funding, revised laws that concerned the control of infectious diseases, implemented the world's largest internet-based disease reporting system to improve transparency, reach and speed, and started a program to rebuild local public health facilities and national infrastructure.

Health in Afghanistan remains poor but steadily improving. It has been negatively affected by the nation's environmental issues and the decades of war since 1978. The Ministry of Public Health (MoPH) oversees all matters concerning the health of the country's residents. The Human Rights Measurement Initiative finds that Afghanistan is fulfilling 72.5% of what it should be fulfilling for the right to health based on its level of income.

<span class="mw-page-title-main">Health in Vietnam</span>

Health in Vietnam encompasses general and specific concerns to the region, its history, and various socioeconomic status, such as dealing with malnutrition, effects of Agent Orange as well as psychological issues from the Vietnam War, tropical diseases, and other issues such as underdeveloped healthcare systems or inadequate ratio of healthcare or social workers to patients.

EXPAND-TB is a UNITAID-funded project launched in 2009, which aims to increase access to tuberculosis (TB) diagnostic tests in 27 endemic countries.

<span class="mw-page-title-main">Tuberculosis in India</span> Health issue in India

Tuberculosis in India is a major health problem, causing about 220,000 deaths every year. In 2020, the Indian government made statements to eliminate tuberculosis from the country by 2025 through its National TB Elimination Program. Interventions in this program include major investment in health care, providing supplemental nutrition credit through the Nikshay Poshan Yojana, organizing a national epidemiological survey for tuberculosis, and organizing a national campaign to tie together the Indian government and private health infrastructure for the goal of eliminating the disease.

Operation ASHA(OpASHA) is a non-profit organization (NGO) founded in 2006 to bring tuberculosis (TB) treatment at economically feasible rates to disadvantaged communities. The organization's primary work is to detect and cure TB, as well as to prevent and treat multidrug-resistant tuberculosis (MDR-TB) in India and Cambodia. Operation ASHA specializes in last-mile connectivity, bridging the gap between government medicine distribution centers and the communities of patients to deliver treatment at the doorsteps of the under-served. In addition to detecting and curing TB, OpASHA's community health workers also educate the community about TB and its symptoms thereby helping to reduce the stigma there is regarding the disease. In addition to TB, Operation ASHA's model and technology has been used in many other diseases such as diabetes, hemophilia and mental health.

Delamanid, sold under the brand name Deltyba, is a medication used to treat tuberculosis. Specifically it is used, along with other antituberculosis medications, for active multidrug-resistant tuberculosis. It is taken by mouth.

This page is a timeline of global health, including major conferences, interventions, cures, and crises.

Tuberculosis elimination is the effort to reduce the number of tuberculosis (TB) cases to less than one per 1 million population, contrasted with the effort to completely eradicate infection in humans worldwide. The goal of tuberculosis elimination is hampered by the lack of rapid testing, short and effective treatment courses, and completely effective vaccine. The WHO as well as the Stop TB Partnership aim for the full elimination of TB by 2050—requiring a 1000-fold reduction in tuberculosis incidence. As of 2017, tuberculosis has not been eliminated from any country.

References

  1. ↑ "Stop TB Partnership". www.stoptb.org.
  2. ↑ "The Board | Stop TB Partnership". www.stoptb.org. Retrieved 2024-01-23.
  3. ↑ "Dr. Lucica Ditiu, Executive Director of the Stop TB Partnership, on the Global Impact of Tuberculosis - Press Conference | UN Web TV". webtv.un.org. 2023-05-04. Retrieved 2024-01-23.
  4. ↑ "Stop TB Partnership - About the Stop TB Partnership". Archived from the original on 2009-06-06. Retrieved 2009-06-20.
  5. ↑ "User account | Stop TB Partnership". www.stoptb.org.
  6. ↑ "Global Plan to End TB | Stop TB Partnership". www.stoptb.org. Retrieved 2024-01-17.
  7. ↑ Raithby, Leigh; September 2023, Evaline Kibuchi // 07 (2023-09-07). "Opinion: We won't get the innovation needed to end TB without more R&D". Devex. Retrieved 2024-01-17.{{cite web}}: CS1 maint: numeric names: authors list (link)
  8. ↑ Ditiu, Dr Lucica; April 2023, Farhana Amanullah // 27 (2023-04-27). "Opinion: No more excuses — we can end TB in children". Devex. Retrieved 2024-02-08.{{cite web}}: CS1 maint: numeric names: authors list (link)
  9. ↑ "Global Drug Facility (GDF) | Stop TB Partnership". www.stoptb.org. Retrieved 2024-02-08.
  10. ↑ UN General Assembly Political Declaration on Tuberculosis
  11. ↑ "Major price cut announced for critical drug for resistant TB | CIDRAP". www.cidrap.umn.edu. 2023-08-30. Retrieved 2024-02-08.
  12. ↑ Menjíbar, Diego (2023-12-09). "Mozambique prison: "With so many people, it's hard to know who has tuberculosis."". EL PAÍS English. Retrieved 2024-02-08.
  13. ↑ "Fund TB Communities & Civil Society | Stop TB Partnership". www.stoptb.org. Retrieved 2024-02-08.
  14. ↑ "Stop TB Partnership launches Challenge Facility for Civil Society Round 8 - Women4GlobalFund". 2017-12-07. Retrieved 2024-02-08.
  15. ↑ "TB Online - Challenge Facility for Civil Society Round 12". www.tbonline.info. Retrieved 2024-02-08.
  16. ↑ "Stop TB Partnership - July 2009 review | GiveWell". www.givewell.org.
  17. ↑ "Stop TB Partnership | GiveWell". www.givewell.org.
  18. ↑ Mandavilli, Apoorva (2020-09-12). "A Global Health Star Under Fire". The New York Times. ISSN   0362-4331 . Retrieved 2023-12-13.
  19. ↑ Mandavilli, Apoorva (2020-09-12). "A Global Health Star Under Fire". The New York Times. ISSN   0362-4331 . Retrieved 2023-12-13.
  20. ↑ "Treatment Action Group Condemns Reported Bullying, Harassment, and Racism at Stop TB Partnership". Treatment Action Group. Retrieved 2024-01-24.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.